Business
Humacyte Announces First Quarter 2026 Financial Results and Provides Business Update
- Appointed Jim Mercadante as Chief Commercial Officer and Dr. Todd Rasmussen as Chief Surgical Officer - - First quarter sales of Symvess® were $0.5 million
About this update from Humacyte, Inc.
[{"type":"text","content":"- Appointed Jim Mercadante as Chief Commercial Officer and Dr. Todd Rasmussen as Chief Surgical Officer - - First quarter sales of Symvess® were $0.5 million in 2026 compared to $0.1 million in 2025 - - Purchase commitment received for a minimum of $1.475 million for a clinical evaluation and outreach program in the Kingdom of Saudi Arabia - - Announced Israeli Ministry of Health Acceptance of Marketing Authorization Application for Symvess for Vascular Injury Repair - - U.S. Department of Defense funding for procurement of bioengineered blood vessels - - Major milestone upcoming: Top-line interim results from V012 Phase 3 study in hemodialysis access - -Conference call today at 8:00 am ET - DURHAM, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced financial results for the first quarter ended March 31, 2026, and provided a business update. “We have seen expansion in the commercial uptake of Symvess. We also recognize that more rapid growth and expansion of sales is necessary and warranted, based on this innovative product’s potential,” said Laura Niklason, M.D., Ph.D., Founder and Chief Executive Officer of Humacyte. “Therefore, as recently announced, we have made substantial hires in senior commercial and surgical leadership positions including industry veteran James Mercadante as Chief Commercial Officer and Dr. Todd Rasmussen as Chief Surgical Officer. Jim is an accomplished medtech commercial leader with an extensive track record of field-specific success in vascular and cardiothoracic surgery markets. Dr. Rasmussen is one of the trailblazers of modern vascular surgery and will be instrumental in guiding scientific strategy and real-world implementation of Symvess going forward. We look forward to working with both of our new leaders to accelerate and expand patient access to Symvess.” “We are nearing one of the most exciting milestones in Humacyte’s history, the presentation of top-line interim results of our Phase 3 trial in hemodialysis access June 11, 2026 at the Society of Vascular Surgery’s (SVS) Vascular Annual Meeting (VAM) in Boston. We also continue to work toward commencement of our Phase 1/2 trial of the CTEV in coronary artery bypass surgery i...